GH Stock Recent News
GH LATEST HEADLINES
Guardant Health Inc.'s stock rose 2.4% Monday, after the company said the Food and Drug Administration has approved its blood test for colon-cancer screening in adults 45 and older who are at average risk for the disease.
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.
On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to boost the rate of screenings for the disease as fewer eligible Americans opt for colonoscopies.
The U.S. Food and Drug Administration on Monday approved Guardant Health's blood test to detect a cancer that starts in the colon or rectum.
PALO ALTO, Calif.--(BUSINESS WIRE)--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in a.
After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.